New antibiotic launched for C diff
The first in a new class of antibiotics was launched in the UK last week for the treatment of Clostridium difficile infection.
Fidaxomicin (Dificlir) is manufactured by Astellas Pharma. In a statement announcing the drug’s launch, the company said fidaxomicin demonstrated a similar efficacy and safety profile to vancomycin in trials.
But fidaxomicin more than halved the rate of infection recurrence compared to vancomycin, 12.7% versus 26.9%.